CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
47.91
-2.52 (-5.00%)
At close: Feb 21, 2025, 4:00 PM
47.67
-0.24 (-0.50%)
After-hours: Feb 21, 2025, 7:45 PM EST
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 75.42, with a low estimate of 32 and a high estimate of 120. The average target predicts an increase of 57.42% from the current stock price of 47.91.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 2 | 2 | 2 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 18 | 19 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 19, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $89 → $82 | Strong Buy | Maintains | $89 → $82 | +71.15% | Feb 18, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $30 → $32 | Sell | Maintains | $30 → $32 | -33.21% | Feb 14, 2025 |
| Evercore ISI Group | Evercore ISI Group | Hold → Buy Upgrades $60 → $99 | Hold → Buy | Upgrades | $60 → $99 | +106.64% | Feb 14, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $66 → $57 | Hold | Maintains | $66 → $57 | +18.97% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
122.30M
from 37.31M
Increased by 227.76%
Revenue Next Year
554.08M
from 122.30M
Increased by 353.05%
EPS This Year
-5.00
from -4.34
EPS Next Year
-4.17
from -5.00
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 692.6M | 5.7B | 8.3B | ||
| Avg | 122.3M | 554.1M | 1.0B | ||
| Low | n/a | 46.9M | 98.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,756.1% | 4,572.9% | 1,397.1% | ||
| Avg | 227.8% | 353.0% | 84.6% | ||
| Low | - | -61.6% | -82.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.51 | 4.15 | 5.79 | ||
| Avg | -5.00 | -4.17 | -2.09 | ||
| Low | -6.80 | -7.54 | -6.59 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.